The murine monoclonal antiplatelet antibodies MA-TSPI-1 (directed against human thrombospondin) and MA-PMI-2, MA-PMI-1, and MA-LIBS-1 (directed against ligand-induced binding sites [LIBS] on human platelet glycoprotein Ilb/llla) were conjugated with recombinant single-chain urokinasetype plasminogen activator (rscu-PA) using the cross-linking reagent N-succinimidyl3-(2-pyridyldithio)propionate (SPDP). The conjugates (rscu-PA/MA-TSPI-1, rscu-PAIMA-PMI-2, rscu-PA/MA-PMI-1, and rscu-PA/MA-LIBS-1), purified by immunoadsorption and gel filtration, were obtained with recoveries of 34% t o 45%. with an average stoichiometry of 1.6 t o 1.8
P cardiovascular diseases.' Platelet-rich regions of a thrombus appear to be very resistant to thromb~lysis.~' In addition, platelet deposition may contribute to coronary artery reocclusion following successful thrombolytic therapy in patients with acute myocardial infarction.' Successful targeting of plasminogen activators to a thrombus by conjugation with monoclonal antibodies (MoAbs) directed against fibrin has been previously reported. Chemical conjugates of tissue-type plasminogen activator (t-PA) or of urokinase-type plasminogen activator (u-PA) with specific anti-fibrin antibodies indeed have a significantly enhanced fibrinolytic potency towards fibrin clots in in vitro ~y s t e m s~.~ and in animal models in vivo. ',' MoAbs that recognize epitopes present on the surface of activated platelets, but not of resting platelets, might represent a targeting vector for thrombolytic agents towards platelet-rich clots. In the present study, we have conjugated recombinant single-chain u-PA (rscu-PA) to an MoAb (MA-TSPI-1) directed against human thrombospondin: a platelet+-granule glycoprotein that is expressed on the surface of stimulated platelets but minimally on the surface of resting
In addition, rscu-PA was conjugated to three different MoAbs recognizing the platelet surface glycoprotein GPIIb/IIIa when this receptor is occupied by fibrinogen or other adhesive proteins; MA-PMI-1 is directed against GPIIba," and MA-PMI-2 and MA-ligand-induced binding site-1 (MA-LIBS-1) are directed against GPIIIa.'' The biochemical properties of the four conjugates were evaluated as well as their effect on platelet aggregation, and their fibrinolytic potency towards platelet-rich plasma clots in an in vitro system and in an animal model in vivo.
plasma clot immersed in normal human plasma, the conjugates had threefold t o greater than 15-fold less fibrinolytic potency than unconjugated rscu-PA. The thrombolytic potency of rscu-PA/MA-PMI-1 and rscu-PA/MA-LIBS-l was compared with that of rscu-PA and that of a control conjugate rscu-PA/MA-lC8 in a pulmonary embolism model in the hamster, using clots prepared from platelet-poor or plateletrich human plasma. Lysis was measured 30 minutes after the end of a 60-minute intravenous infusion of the thrombolytic agents. rscu-PA, rscu-PA/MA-PMI-1, rscu-PAIMA-LIBS-1, as well as rscu-PA/MA-lCI had comparable thrombolytic potencies (percent lysis per dose administered) towards plateletpoor human plasma clots. In contrast, the thrombolytic potency of rscu-PA/MA-PMI-1 and of rscu-PAIMA-LIBS-1 towards platelet-rich clots was 2.3-t o 3-fold higher than that of rscu-PA (P < .005) and fivefold t o sevenfold higher than that of the control conjugate (P < .01). 6 1991 by The American Society of Hematology.
MATERIALS AND METHODS

Proteins and Reagents
rscu-PA, prepared by expression of cDNA encoding scu-PA in Escherichia coli, was a gift from Griinenthal AG (Aachen, Germany). Recombinant human t-PA (rt-PA) was Activase, kindly supplied by Genentech Inc (South San Francisco, CA). The murine MoAbs MA-TSPI-1, MA-PMI-1, MA-PMI-2, MA-LIBS-1, and MA-1C8 were prepared and characterized as previously des~ribed.6,~,",'* Human plasminogen, plasmin, fibrinogen, and cyanogen bromide (CNBr)-digested fibrinogen were obtained and characterized as previously described."." Bovine thrombin was Topostasin (Hoffmann-La Roche, Basel, Switzerland). rscu-PA, the antibodies MA-TSPI-1, MA-PMI-2, MA-PMI-1, MA-LIBS-1, and MA-1C8, and the conjugates of the antibodies with rscu-PA were radiolabeled using the iodogen method.I4 '"I-labeled fibrin-
Preparation of the Conjugates
rscu-PA and the antibodies MA-TSPI-1, MA-PMI-2, MA-PMI-1, or MA-LIBS-1 were conjugated with the heterobifunctional cross-linking reagent SPDPI6 using a three-step procedure as described previously,6 but with minor modifications: (1) introduction of 2-pyridyl disulphide groups in rscu-PA by treating the protein at a concentration of 1 mg/mL (containing approximately 10' cpm of 'Z51-labeled rscu-PNmL), with a fourfold molar excess of SPDP (degree of substitution: 1 to 3 pyridyl-disulphide [PDP] groups per molecule rscu-PA); (2) introduction of thiol groups in the antibodies with a 10-fold molar excess of SPDP (degree of substitution: 3 to 5.5 PDP groups per IgG molecule), followed by specific reduction of the protein-bound PDP disulphide bonds (degree of substitution: 2.9 to 5.5 thiol groups per IgG molecule); and (3) conjugation by overnight incubation of thiolated antibody with the PDP-derivative of rscu-PA in a 1:l molar ratio. Remaining reactive thiol-groups were then alkylated by addition of 1/100 (vol/vol) of 0.1 mol/L sodium iodoacetate. Alternatively, rscu-PA was conjugated to the control antibody MA-1C8 using the same procedure.
Punjication of the Conjugates
Each of the reaction mixtures was applied to a 5-mL Sepharose 4B column, coupled to the u-PA-specific MoAb MA-4D1E8I7 (2 mg antibody/mL Sepharose) in 0.1 mol/L sodium phosphate, 0.1 mol/L NaCl buffer, pH 7.5, containing 10 kallikrein inhibitor units/mL aprotinin (buffer A) at 4°C. About 2 mg total protein was applied per milliliter of gel. Bound rscu-PA (both conjugated and unconjugated) was eluted with 1.6 mol/L KSCN in buffer A and dialyzed extensively against buffer A. The partially purified conjugates were then gel-filtered at 4°C on Sephacryl S-200 superfine in 0.1 mol/L sodium phosphate buffer, pH 7.5, containing 0.1 mol/L NaCl(5 to 15 mg total protein was applied in a volume of 2 mL to a 1.4 x 75 cm column). The pooled purified conjugates were concentrated by centrifugation on Centricon 30 microconcentrators (Amicon, Danvers, MA).
Analytical Techniques
scu-PA concentration in the conjugate was determined from the specific radioactivity. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 7.5% gels without reduction, and on 10% to 15% gradient gels after reduction with dithioerythritol, using the Phast System (Pharmacia). Immunoblotting on nitrocellulose sheets was performed according to Towbin et a1.I' Specific fibrinolytic activities of u-PA moieties were determined on fibrin plates" by comparison with the International Reference Preparation for Urokinase. The rscu-PNantiplatelet antibody conjugates were tested after inhibition of trace amounts of two-chain activity with Glu-Gly-Arg-CH,CI and removal of excess inhibitor by washing on Centricon 30 microconcentrators.
Functional Characterization of the Conjugates
Treatment with plasmin. rscu-PNMA-TSPI-1, rscu-PNMA-PMI-2, rscu-PAA4A-PMI-1, rscu-PNMA-LIBS-1, or rscu-PA (final concentration 2 pmoVL u-PA equivalent) were treated at 37°C with plasmin (0% to 5% molar ratio) in 0.05 mol/L Tris-HCI buffer, pH 7.4, containing 0.038 mol/L NaCl and 0.01% Tween 80. At timed intewals (0 to 20 minutes) the urokinase-like amidolytic activity was measured with the chromogenic substrate S-2444 (final concentration, 0.3 mmol/L) after 160-fold dilution of the samples. Urokinase activity was expressed in IU by comparison with the International Reference Preparation for Urokinase.
Activation of plasminogen (final concentration, 0.25 to 1.5 pmol/L) was measured with rscu-PA, rscu-PNMA-TSPI-1, rscu-PNMA-PMI-2, rscu-PAMA-PMI-1, or rscu-PNMA-LIBS-1 (final u-PA concentration, 5 to 20 nmol/L) at 37°C in 0.05 mol/L Tris-HCI buffer, pH 7.4, containing 0.038 mol/L NaCI, 0.01% Tween 80, and 1 mmoVL S-2251." Generation of plasmin was monitored continuously for 3 to 4 minutes by measuring the absorbance at 405 nm. Before use, traces of two-chain derivatives in the conjugates were inhibited by addition of the urokinase inhibitor Glu-Gly-Arg-CH,CI as described above.
The effect of platelets on the rate of plasminogen activation was determined by incubating plasminogen (final concentration, 1.5 pmol/L) in the presence or absence of freshly prepared, washed human platelets (final platelet count 3 x l@/pL) with rscu-PA, rscu-PNMA-PMI-1, rscu-PNMA-LIBS-1, or rscu-PAMA-lC8 (final u-PA concentration, 5 nmom) at 37°C in 0.05 mol/L Tris-HC1 buffer, pH 7.4, containing 0.038 moVL NaCI, 0.01% Tween 80, and 0.1 U/mL thrombin. At different time intervals (0 to 10 minutes) samples were removed, centrifuged for 30 seconds, and the amount of plasmin generated was measured with the substrate S-2251 after 20-fold dilution of the samples. Initial activation rates were obtained from plots of the concentration of generated plasmin versus time. Activation of plasminogen (final concentration, 1 pmol/L) was measured in the same way in the presence or absence of platelets with rt-PA (final concentration, 10 nmol/L).
The effect of fibrin on the rate of plasminogen activation was determined by incubating plasminogen (final concentration, 1.5 pmol/L) in the presence or absence of CNBr-digested fibrinogen (final concentration, 1 pmol/L) with rscu-PA (final concentration, 0.2 nmol/L), rscu-PA/MA-PMI-1, rscu-PNMA-LIBS-1, or rscu-PA/ MA-1C8 (final u-PA concentration, 1 nmol/L) at 37°C in 0.05 m o m Tris-HC1 buffer, pH 7.4, containing 0.038 mol/L NaCl and 0.01% Tween 80. CNBr-digested fibrinogen has been shown to be a valid alternative for solid phase fibrin in kinetic experiments." At different time intervals (0 to 15 minutes) samples were removed for quantification of the amount of plasmin generated. Therefore, the sample was diluted eightfold in 0.05 mol/L Tris-HC1 buffer, pH 7.4,
Activation of plasminogen.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From containing 0.038 m o l t NaCl, 0.01% Tween 80, and 1 mmoVL S-2251. After incubation for 3 minutes at 37°C the hydrolysis of the substrate was arrested by addition of acetic acid to a final concentration of 15% and the absorbance was measured at 405 nm. Absorbance at 405 nm was converted to plasmin concentration using a calibration curve constructed with purified plasmin. Initial activation rates were obtained as described above. Activation of plasminogen (final concentration, 1 pmoVL) was measured in the same way in the presence or absence of CNBr-digested fibrinogen with rt-PA (final concentration, 25 nmoVL in the absence or 0.25 nmol/L in the presence of 1 pmoVL CNBr-digested fibrinogen).
Binding experiments with MA-PMI-1, MA-PMI-2, MA-LIBS-1, or their conjugates with rscu-PA were performed in microtiter plates coated with thrombinstimulated, formaldehyde-fixed human platelets. The assay plates were prepared by addition of 100-pL aliquots of a modified Tyrode's buffer (134 mmol/L NaC1, 12 mmoVL NaHCO,, 2.9 mmol/L KCI, 0.34 mmoVL Na,HPO,, 5 mmol/L HEPES, pH 7.4) containing 5 x lo6 washed platelets to the wells of a 96-well microtiter plate precoated with poly-L-lysine (1 pg per well). The plates were centrifuged at 1,000 rpm for 15 minutes at 10°C, and the platelets were activated by addition of 5 pL per well of an a-thrombin solution of 100 U/mL. After incubation for 15 minutes at room temperature, the platelets were fixed by addition of formaldehyde (50 pL of a 0.5% solution per well) and further incubated for 15 minutes at room temperature. The plates were then washed with phosphate-buffered saline (PBS) containing 0.002% Tween 80, and saturated with 200 pL of 3% gelatin per well. After incubation for 1 hour at room temperature and 30 minutes at 3 7 T , the plates were washed and used in the binding assay.
For binding experiments with the anti-thrombospondin antibody MA-TSPI-1 or its conjugate with rscu-PA, platelet releasate was used instead of whole platelets. Therefore, washed human platelets, suspended in PBS at a platelet count of 5 x 106/pL, were stimulated with thrombin (final concentration, 5 U/mL) and after incubation for 10 minutes at room temperature, the suspension was centrifuged for 10 minutes at 3,000 rpm. The platelet-free supernatant was diluted %fold with PBS, and 100-pL aliquots of the diluted releasate were added to the wells of a 96-well microtiter plate. M e r overnight incubation at 4"C, the plate was washed four times with 200 pL/well of 0.01 mol/L sodium phosphate buffer, pH 7.3, containing 0.02% azide, 0.05% Tween 20, and 0.1% bovine serum albumin (BSA), and saturated with 3% gelatin as described above.
The binding of the antibody moieties to their antigen was evaluated in competition experiments. Therefore, 12sI-labeled unconjugated MoAb (12.5 ng) was mixed in PBS containing 0.002% Tween 80 and 0.1% BSAin a total volume of 25 pL, with either the corresponding unlabeled antibody (0 to 3.75 pg) or with the corresponding rscu-PA conjugate (0 to 3.75 pg antibody equivalent). The mixtures were then incubated for 1 hour at room temperature in wells of microtiter plates coated with thrombinactivated platelets as described above (for experiments with MA-PMI-2, MA-PMI-1, or MA-LIBS-1) or with platelet releasate (for experiments with MA-TSPI-1). After extensive washing, bound MoAb was quantitated by measurement of the radioactivity associated with the wells.
Binding to platelets in a plasma milieu was evaluated with the antibodies MA-PMI-1, MA-LIBS-1, and MA-1C8 and with the conjugates of rscu-PA with these antibodies. Platelet-rich human plasma was freshly prepared from blood collected on acid-citrate-dextrose and was diluted with platelet-poor plasma from the same donor to a platelet count of Binding of the conjugates to their antigen.
Binding of the conjugates to humanplatelets.
3 X 105/pL. One-hundred microliter aliquots, containing 3 x lo' platelets, were incubated, in the presence of aprotinin (final concentration, 20 kallikrein inhibitor units/mL), with 5 pg unconjugated antibody or 5 pg antibody equivalent of the conjugate (containing 30,000 to 400,000 cpm of radiolabeled ligand) in a final volume of 150 pL. Platelets were used either stimulated (in the presence of ADP at a final concentration of 10 pmol/L) or unstimulated (without addition of ADP and in the presence of prostaglandin E, and aspirin at a final concentration of 1 pmol/L and 14 "ow, respectively). Following 30 minutes of incubation at room temperature, bound ligand was separated from unbound by layering the sample over 250 pL silicone oil (3 volumes silicone oil, d.1.05; Janssen Chimica, Beerse, Belgium; mixed with 1 volume olive oil PB v; Vel, Leuven, Belgium) in 1.5-mL Eppendorf tubes.
The samples were then centrifuged for 5 minutes in an Eppendorf centrifuge. The supernatant was decanted by inversion and the tips of the tubes (containing the platelets) were amputated and counted in a gamma counter.
Binding to platelet-poor or platelet-rich human plasma clots was evaluated with the antibodies MA-PMI-1, MA-LIBS-1, and MA-1C8 and with the conjugates rscu-PNMA-PMI-I, rscu-PA/MA-LIBS-I, and rscu-PAiMA-lC8. Plasma clots were produced by mixing either platelet-poor human plasma (fresh-frozen citrated blood bank plasma) or freshly prepared platelet-rich human plasma (diluted with platelet-poor plasma to a platelet count of 3 x 105/pL) with CaCI, (final concentration, 38 mmol/L) and thrombin (final concentration, 2 U/mL). The solution was immediately drawn into Silastic tubing (inner diameter, 4 mm) and incubated for 1 hour at 37°C. The silastic tubing containing clotted platelet-poor or platelet-rich plasma was then cut into 0.5-cm sections, yielding clots of about 0.1 mL. After removal from the tubing sections, the clots were washed in 0.05 mol/L Tris-HC1 buffer, pH 7.4, containing 0.038 mol/L NaCl and 0.01% Tween 80 and each clot was suspended in 0.5 mL citrated normal human plasma containing m o w urokinase inhibitor Glu-Gly-Arg-CH,CI, IO-' mol/L thrombin inhibitor PPACK, and aprotinin at 20 kallikrein inhibitor units/mL. The assay was initiated by addition of 300 ng 1Z51-labeled unconjugated antibody (200,000 to 500,000 cpm) or 300 ng antibody equivalent of '2SI-labeled conjugate (30,000 to 150,000 cpm). Following 2 hours of incubation at 3 7 T , the clots were washed extensively with 0.05 molLTris-HC1 buffer, pH 7.4, containing 0.038 molL NaCl, 0.01% Tween 80, and aprotinin at 20 kallikrein inhibitor unitsiml, and counted for radioactivity.
Platelet-rich plasma (125 pL, platelet count 3 to 6 x 10s/pL) was preincubated for 30 minutes at room temperature with rscu-PA (final concentration, 1 to 300 pg/mL) with the antibodies MA-TSPI-1, MA-PMI-2, MA-PMI-1, or MA-LIBS-1 (final concentration, 3 to 300 pg/mL), or with their conjugates with rscu-PA (final concentration, 0.1 to 300 pg u-PA equivalent/mL), in a final volume of 250 pL. As a control, platelet-rich plasma was preincubated with 0.1 mol/L sodium phosphate buffer, pH 7.5, containing 0.1 molL NaC1. ADP was then added at the minimal concentration required for full aggregation, and platelet aggregation was monitored for about 4 minutes at 37°C by measurement of the light transmittance using an Elvi 840 dual channel aggregometer (Elvi, Milan, Italy). The extent of aggregation was determined as the change in light transmittance measured 3 minutes after addition of ADP, expressed in percent of the difference between platelet-rich and platelet-poor plasma, and calculated as percent of the control value (preincubation with buffer).
Lysis of '251-jbrin labeled human plasma clots in aplasma milieu in vitro. 1251-fibrin-labeled platelet-rich plasma clots were prepared Binding of the conjugates to human plasma clots.
Platelet aggregation assay.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From from freshly prepared platelet-rich human plasma (diluted with platelet-poor plasma to a platelet count of 1 to 3 x 1@/pL or enriched by centrifugation to a platelet count of 6 to 15 x l@/p,L). '%ibrin-labeled platelet-poor plasma clots were prepared from normal human plasma (fresh-frozen citrated blood bank plasma, platelet count i O . 3 x l@/pL). Lysis of 0.1 mL clots, immersed in 0.5 mL citrated normal human plasma, with rscu-PA, rscu-PNMA-TSPI-1, rscu-PNMA-PMI-2, rscu-PNMA-PMI-1, rscu-PAMA-LIBS-1, or rscu-PNMA-1C8 was measured after 2 hours of incubation at 37"C, as described elsewhere.21 Fibrinogen levels were determined with a clotting rate assay?2 To investigate a potential effect of unconjugated antibody on the lysis of plateletrich clots obtained with rscu-PA, it was mixed at a final concentration of 0.8 pg/mL with MA-TSPI-1, MA-PMI-2, MA-PMI-1, or MA-LIBS-1 in a twofold or fourfold molar excess of antibody over rscu-PA before addition to the clot lysis system.
Lysis of 12s1-fibrin-labeled human platelet-rich or platelet-poor plasma clots in a hamster pulmonary embolism model. Evaluation of the thrombolytic potency of rscu-PA, rscu-PNMA-PMI-1, rscu-PNMA-LIBS-1, or rscu-PNMA-lC8 towards human plasma clots in vivo was performed using the pulmonary embolism model in the hamster as described previo~sly:~ with clots prepared either from fresh platelet-rich human plasma (platelet count, 3 x 105/1*.L) or from normal human plasma (platelet-poor) containing traces of 'ZSI-labeled fibrinogen. Briefly, a 25 pL '251-fibrin-labeled human plasma clot was produced in vitro and injected into the jugular vein of heparinized outbred hamsters. Thrombolytic agents were infused intravenously over 60 minutes and lysis was measured 30 minutes after the end of the infusion as the difference between the radioactivity initially incorporated in the clot and the residual radioactivity in the lungs and the heart. Fibrinogen and "2-antiplasmin levels in plasma from blood samples taken at the end of the experiment were determined using the Automated Coagulation Laboratory (ACL; Instrumentation Laboratory, Milan, Italy) as recommended by the manufacturer, but with minor modifications. u-PA-related antigen in plasma samples was measured with a specific enzyme-linked immunosorbent assay (ELISA).''
The relative thrombolytic potency (lysis per u-PA equivalent administered) and the specific thrombolytic activity (lysis per pg/mL plasma u-PA antigen level) of the compounds was expressed in the following way. The individual dose-response data (percent lysis versus dose in mgkg and percent lysis versus steady state u-PA-related antigen in pg/mL) were corrected for background lysis and the corrected data were fitted with a linear regression line forced through the origin. The significance of the differences between the regression line slopes was determined using Student's t-test.
RESULTS
Purification of the Conjugates
Chemical conjugation of rscu-PA with the antiplatelet antibodies was performed using batches of 2.6 to 6.5 mg of the plasminogen activator and 7 to 19 mg of the antibody, as described in Materials and Methods. After overnight incubation at room temperature, the reaction mixtures containing the conjugates were chromatographed on insolubilized anti-urokinase antibody, MA-4DlE8. This protocol resulted in recoveries of rscu-PA between 60% and 67% (Table 1) as determined from the recovery of "'I. After further purification on Sephacryl S-200 superfine, recoveries of rscu-PA ranged between 23% and 31% and recoveries of total protein between 34% and 45% ( Table 1) . Purification of rscu-PA/MA-lC8 is described elsewhere? 
The data represent mean 2 SD of percent recovery obtained with three preparations of each conjugate.
Physicochemical Characterization of the Conjugates
SDS-PAGE of the conjugates under nonreducing conditions ( Fig 1A) showed a similar migration pattern for each of the conjugates, with a main band with a mobility between that of ferritin and of the unconjugated antibodies (lanes 2, 4, 6, and 8). SDS-PAGE under reducing conditions ( Fig  1B) showed the dissociation of the conjugates into their constituents, the heavy and light chains of the antibody with M, approximately 50,000 and 25,000, and rscu-PA, migrating below the heavy chain of the antibody. Immunoblotting of nonreduced SDS-PAGE with horseradish peroxidaselabeled goat antimouse IgG (Fig 2A) or with anti-u-PA antiserum (Fig 2B) confirmed the presence of both mouse IgG and u-PA material in the conjugates. Trace amounts of unconjugated rscu-PA were observed in all four conjugates. The stoichiometry of IgG and rscu-PA in the conjugates, as determined from the ratio of the rscu-PA content (measured as 1 2 ' I -r~~~-P A ) and the IgG content (determined as the difference between total protein, calculated from the absorbance at 280 nm, and rscu-PA protein), was 1.8 ? 0.6, 1.6 ? 0.3,1.6 2 0.25, and 1.6 ? 0.1 (mean ? SD, n = 3) IgG moleculesirscu-PA molecule for rscu-PA/MA-TSPI-1, rscu-PA/MA-PMI-2, rscu-PA/MA-PMI-1, and rscu-PA/MA-LIBS-1, respectively.
Functional Characterization of the Conjugates
Treatment of the conjugates with plasmin. Plasmin caused a time-and concentration-dependent conversion of rscu-PA/ MA-TSPI-1, rscu-PA/MA-PMI-2, rscu-PA/MA-PMI-1, rscu-PA/MA-LIBS-1 (Fig 3) , and rscu-PA (not shown) to amidolytically active two-chain derivatives with an increase in specific activity from less than 2,500 IU/mg to 83,000 jl: 15,000 IU/mg u-PA equivalent for rtcu-PAMA-TSPI-1, to 70,000 -C 9,200 IU/mg u-PA for rtcu-PA/MA-PMI-2, to 100,000 ? 5,500 IU/mg u-PA for rtcu-PAMA-PMI-1, and to 120,000 -r-6,400 IU/mg u-PA for rtcu-PAMA-LIBS-1, as compared with 100,000 ? 9,800 IU/mg for rtcu-PA (mean ? SEM, n = 3) and 94,000 IU/mg for rtcu-PA/MA-1CK6 Maximal activation with plasmin coincided with quantitative conversion of the scu-PA moieties to two-chain 
derivatives, as confirmed by SDS-PAGE under reducing conditions (not shown).
Initial activation rates were derived from linear plots of generated tcu-PA (expressed in nmol/L) versus time, using the values obtained within 2 or 3 minutes after addition of each of the plasmin concentrations (not shown). The initial activation rates, expressed in nmol/L of tcu-PA generated per minute per nmol/L of plasmin, obtained with the conjugates were comparable with that obtained with m u -PA: 12 e 4 for rscu-PAIMA-TSPI-1. 12 2 4.7 for rscu-PA/ MA-PMI-2.15 -C 5.8 for rscu-PAJMA-PMI-1 and 18 e 5 for mu-PAIMA-LIBS-1 (mean e SD, n = 3). as compared with 30 e 13 for rscu-PA (mean e SD, n = 6) and 8.5 for rscu-PAIMA-1C8 (n = 2).
The specific fibrinolytic activities on fibrin plates, expressed per milligram of u-PA, were 92,000 IU for rscu-PA/MA-TSPI-1, 120,000 IU for
Specijic fibrinolyric activities.
rscu-PAIMA-PMI-2, 100,OOO IU for rscu-PA/MA-PMI-1, and 91,000 IU for rscu-PAIMA-LIBS-1 (n = 2), as compared with 88,000 e 16,000 IU for rscu-PA (mean 2 SD, n = 5) and to 65,OOO IU for rscu-PAIMA-1C8 (n = 2):
Activation of plasminogen by the conjugata obeyed Michaelis-Menten kinetics as cvidcnced by lincar double reciprocal plots of the activation rate versus the plasminogen concentration (not shown). Plasminogen activation by rscu-PA, rscu-PAIMA-PMI-1, mu-PNMA-LIBS-1, or rscu-PAIMA-1C8 was not altered in the presence of human platelets; initial activation rates (expressed in nmol/L of plasmin generated per minute) in the absence or presence of platelets were 27 and 28, respectively, with rscu-PA, 29 and 27 with rscu-PA/MA-PMI-1.26 and 28 with rscu-PA/MA-LIBS-1, and 21 and 22, respectively, with rscu-PAIMA-lC8. With rt-PA in the same system, a 4.7-fold enhancement of the initial activation rate was found in the presence of human platelets (6.6 nmol/L plasmin generated per minute in the prcsence v 1.4 nmol/L per minute in the absence of platelets).
Similarly, plasminogen activation with r s c u -P m A -PMI-1, rscu-PA/MA-LIBS-1, or rscu-PAIMA-lC8 was not altered in the presence of CNBr-digested fibrinogen; initial activation rates without or with CNBr-digested fibrinogen were 1.3 and 1.4 nmol/L, respectively, of plasmin generated per minute with rscu-PAIMA-PMI-1, 1.0 and 1.1 nmol/L plasmin per minute with mu-PAMA-LIBS-1, and 0.56 and 0.58 nmol/L, respectively, of plasmin generated per minute with mu-PA/MA-lC8. Plasminogen activation with mu-PA was threefold higher in the presence of CNBr-digested fibrinogen (0.81 nmol/L per minute in the presence v 0.27 nmol/L per minute in the absence) whereas plasminogen activation with rt-PA was enhanced 66-fold in the presence of CNBr-digested fibrinogen (0.33 nmol/L per minute v 0.005 nmol/L per minute in the absence of CNBr-digested fibrinogen).
Binding of 'BI-labclcd MA-TSPI-1 to insolubilized thrombospondincontaining platelet releasate was inhibited in a concentration-dependent manner by addition of unlabeled MA-TSPI-1 or rscu-PA/MA-TSPI-1 (Fig 4) . Fifty percent reduction of the binding was obtained at a fourfold molar excess for MA-TSPI-1 and at an eightfold molar antibody excess for rscu-PNMA-TSPI-1. No competition was observed with the control MoAb MA-15C5 directed against fragment D-dimer of cross-linked human fibrin' (Fig 4) . Similarly, binding of '"I-labeled MA-PMI-2 ('"I-MA-PMI-2), "'I-MA-PMI-1, or 12'I-MA-LIBS-l to thrombin-
Kinetics ofplasminogen activation.
Binding of the conjugates to their antigen.
For activated formaldehyde-fixed platelets was reduced in a concentration-dependent manner by addition of the corresponding unlabeled antibody or conjugate (Fig 5) . Fifty percent reduction of the binding of "'I-MA-PMI-2 was obtained at a 12-fold molar excess with MA-PMI-2 and at a 45-fold molar excess with rscu-PA/MA-PMI-2 ( Fig 5A) . Fifty percent reduction of the binding of '2ZI-MA-PMI-l was obtained at a 55-fold molar excess with MA-PMI-1 and at a 110-fold molar excess with rscu-PA/MA-PMI-1 ( Fig  5B) . Fifty percent reduction of the binding of '%MA-LIBS-1 was obtained at a sevenfold or at an 11-fold molar excess with MA-LIBS-1 or with rscu-PA/MA-LIBS-1, respectively (Fig 5C) .
Binding to unstimulated or ADP-stimulated platelets in plasma was evaluated with the antibodies MA-PMI-1, MA-LIBS-1, and Binding of the conjugates to human platelets. unconjugated or conjugated antibody (containing 30,000 to 400,000 cpm of radiolabeled ligand) at room temperature in a final volume of 150 pL. Results are summarized in Table  2 . ADP-stimulated platelets bound threefold to fourfold more molecules of rscu-PNMA-PMI-1, MA-LIBS-1, or rscu-PNMA-LIBS-1 than unstimulated platelets (P < .0005). In contrast, binding to stimulated platelets with MA-1C8, rscu-PNMA-1C8, and, surprisingly, with MA-PMI-1 was not increased over the binding to unstimulated platelets. ADP-stimulated platelets bound a fivefold higher number of MA-LIBS-1 molecules than of the control antibody MA-IC8 (P < .0005), whereas this difference was not observed with unstimulated platelets. Binding to ADPstimulated platelets was, respectively, 13-and 18-fold higher with rscu-PA/MA-PMI-1 or rscu-PA/MA-LIBS-1 as compared with the control conjugate rscu-PA/MA-lCS (P < .0005). With unstimulated platelets, binding with rscu-PA/MA-PMI-l or rscu-PA/MA-LIBS-1 was threefold higher than with rscu-PNMA-lC8 (P < .05).
Binding to platelet-poor or platelet-rich human plasma clots (0.1 mL clots containing, respectively, < 3 x lo6 and 3 X lo7 platelets) immersed in 0.5 mL citrated normal human plasma was evaluated with the antibodies MA-PMI-1, MA-LIBS-1, and MA-1C8 and with the conjugates of rscu-PA with these antibodies. Binding, expressed as the number of molecules bound per clot, was calculated from the radioactivity associated with the clot following 2 hours of incubation at 37°C with 300 ng 'ZSI-labeled unconjugated or conjugated antibody. Results are summarized in Table 2 . Binding to platelet-rich clots with rscu-PNMA-PMI-1, MA-LIBS-1, or rscu-PAMA-LIBS-1 was, respectively, twofold (P = .ll), 2.6-fold (P < .0005), or 2.7-fold (P = .002) higher than binding to platelet-poor clots. As compared with platelet-poor clots, binding to platelet-rich clots was not increased with MA-1C8 or rscu-PA/MA-lC8 nor with MA-PMI-1. No differences were observed for binding to platelet-poor clots between MA-PMI-1 or MA-LIBS-1 and the control antibody MA-1C8, or between rscu-PNMA-PMI-1 or rscu-PA/MA-LIBS-1 and the control conjugate rscu-PNMA-lC8. In contrast, with platelet-rich clots binding of MA-PMI-1 or MA-LIBS-1 was twofold to fivefold higher than that of MA-1C8 (P < .015) and binding of rscu-PA/MA-PMI-1 or rscu-PA/MA-LIBS-1 was 2.3-to 3.5-fold higher than that of rscu-PNMA-lC8 (P < .1).
rscu-PA, the antiplatelet antibodies, and the rscu-PNantiplatelet antibody conjugates were tested for their effect on ADPinduced platelet aggregation in platelet-rich plasma. Aggregation was determined as the change in light transmittance measured 3 minutes after the addition of stimulus, expressed in percent of the difference between platelet-rich and platelet-poor plasma. Platelet aggregation decreased to 75% of the control value when the platelets were preincubated for 30 minutes at room temperature with rscu-PA at a concentration of 63 pg/mL (n = 6) (Fig 6A) . No significant effect on aggregation was observed with either MA-TSPI-1, MA-PMI-2, or MA-PMI-1 at concentrations up to 300 pg IgG/mL (Fig 6B) , nor with the conjugate rscu-PNMABinding of the conjugates to human plasma clots.
Efect of the conjugates on platelet aggregation.
For TSPI-1 at concentrations up to 200 pg u-PA/mL (Fig 6A) . Inhibition to 75% of control was obtained at concentrations of 1.2 pg u-PA/mL for rscu-PA/MA-PMI-1 and 6 pg u-PA/mL for rscu-PA/MA-PMI-2, which is 50 and 10 times lower than the equipotent concentration of rscu-PA. With the conjugate rscu-PNMA-LIBS-1, a decrease to 75% of the control value was obtained at a concentration of 7.6 pg u-PA/mL and complete inhibition was obtained at higher concentrations (Fig 6A) . However, this effect could be fully ascribed to the antibody-moiety present in the conjugate (about 34 pg IgG/mL at a concentration of 7.6 pg u-PA/ mL). Indeed, the antibody MA-LIBS-1 itself was also able to fully inhibit aggregation, reaching 75% of the control value at a concentration of 12 pg/mL (Fig 6B) .
Lysis of '251-jibrin4abeled human plasma clots in a plasma milieu in vitro. Clot lysis with rscu-PA, rscu-PA/MA-TSPI-1, rscu-PA/MA-PMI-2, rscu-PA/MA-PMI-1, rscu-PA/ MA-LIBS-1, or rscu-PA/MA-lC8 was assayed in an in vitro system composed of '251-fibrin-labeled plasma clots immersed in normal human plasma. Figure 7A (panel I) represents dose-response curves of clot lysis, expressed as lysis after 2 hours versus the concentration of plasminogen activator, using clots prepared from normal human plasma (platelet-poor clots). Fifty percent clot lysis in 2 hours was obtained with a concentration (expressed in u-PA equivalents) of 1.25 pg/mL (n = 7) for rscu-PA, as compared with 3 pg/mL for rscu-PA/MA-TSPI-1 (n = l), 2 pg/mL for rscu-PA/MA-PMI-2 (n = l), 0.70 pg/mL for r s c u -P a -PMI-1 (n = 3), 1.0 pg/mL for rscu-PA/MA-LIBS-1 (n = 3), or 1.9 pg/mL for rscu-PNMA-lC8 (n = 2) (not shown). Figure 7B (panel I) represents residual fibrinogen levels at 2 hours versus the concentration of plasminogen activator, during lysis of platelet-poor clots. At concentrations yielding 50% clot lysis in 2 hours, residual fibrinogen levels were 75% for rscu-PA, as compared with 40% for rscu-PA/MA-TSPI-1, less than 20% for rscu-PA/MA-PMI-2, rscu-PA/ MA-PMI-1, or rscu-PA/MA-LIBS-1 (Fig 7B, panel I) , and 40% for rscu-PNMA-lC8 (not shown). Figure 7A (panel 11) represents dose-response curves of clot lysis, using clots prepared from platelet-rich plasma with a platelet count of 1 to 3 x 1 0 s /~L (platelet-rich clots). With rscu-PA, 50% lysis in 2 hours was reached at a concentration of 1.2 pg/mL (n = 10). With rscu-PA/MA-LIBS-1, 50% lysis in 2 hours required a concentration of 4 pg u-PA/mL (n = 3). Maximal lysis with rscu-PA/MA-PMI-1 at concentrations up to 16 pg u-PA/mL was only about 45%, and lysis with rscu-PA/MA-TSPI-1 or rscu-PA/ MA-PMI-2 at concentrations up to 8 pg u-PA/mL did not exceed 30%. Lysis in 2 hours with rscu-PA/MA-lC8 at concentrations up to 24 pg u-PNmL did not exceed 25% (not shown). With rscu-PA at the concentration yielding 50% lysis of a platelet-rich clot in 2 hours, a residual fibrinogen level of 83% of the baseline value was measured (Fig 7B, panel 11) . In contrast, extensive fibrinogen breakdown occurred during lysis with rscu-PA/MA-PMI-2, rscu-PNMA-PMI-1, rscu-PA/MA-LIBS-1, and, somewhat less pronounced, with rscu-PA/MA-TSPI-1 (Fig 7B, panel 11) . Lysis with rscu-PNMA-lC8 was also associated with extensive fibrinogen breakdown (not shown). Lysis of plateletrich clots with rscu-PA was not influenced by addition of unconjugated MA-TSPI-1, MA-PMI-2, MA-PMI-1, or MA-LIBS-1 at a twofold to fourfold molar excess of antibody over rscu-PA (not shown), indicating that interaction of the antibodies with a platelet-rich clot did not alter the susceptibility of the clot to lysis by rscu-PA. Figure 7A (panel 111) represents dose-response curves of lysis using clots prepared from platelet-enriched plasma with a platelet count of 6 to 15 x 105/pL (platelet-enriched clots). With rscu-PA at a concentration of 2 pg/mL, lysis in 2 hours reached a maximum of only about 44% (n = 5) and decreased again at higher scu-PA Concentrations. No significant lysis (<20% in 2 hours) was obtained with the rscu-PNantiplatelet antibody conjugates at concentrations up to 32 pg u-PA/mL (Fig 7A, panel 111 ) nor with rscu-PA/MA-lC8 at concentrations up to 24 pg u-PA/mL (not shown). At the concentration of rscu-PA yielding maximal lysis in 2 hours, the level of residual fibrinogen was decreased to 45% of the baseline value (Fig 7B, panel 111 ). Significant fibrinogen breakdown was observed during lysis with each of the four rscu-PNantiplatelet antibody conjugates, which was most pronounced with rscu-PAIMA-PMI-1 and with rscu-PA/MA-LIBS-1 (Fig 7B, panel 111 ). Significant fibrinogen breakdown also occurred during lysis with rscu-PNMA-lC8 (not shown). Lysis of '2sI-$brin-labeled platelet-rich or platelet-poor human plasma clots in a hamster pulmonary embolism model. The in vivo thrombolytic potency of rscu-PAJMA-PMI-1 and rscu-PA/MA-LIBS-1 was compared with that of rscu-PA or of the control conjugate rscu-PA/MA-lC8 in a hamster pulmonary embolism model, in which the pulmonary clot was prepared from platelet-rich (platelet count, 3 x lo'/ pL) or from platelet-poor human plasma. The results obtained with platelet-rich clots are summarized in Table 3 . Twenty-five experiments with saline infusion yielded a value for spontaneous lysis at 90 minutes of 18% ? 2% (mean 2 SEM). Fibrinogen levels at the end of the experiment were 160% ? 13% (n = 13) of the baseline value and a,-antiplasmin levels were 95% ? 5% (n = 14). With mu-PA, lysis at 90 minutes after the start of the infusion increased from 25% c 8% at 0.25 mgikg to 89% t 1% at 4 mgikg. rscu-PA/MA-PMI-1 at a dose of 0.25, 0.5, or 1 mg u-PA equivalentkg resulted in 19% ? 5%, 36% ? 7%, or 85% ? 1% lysis at 90 minutes, respectively. rscu-PNMA-LIBS-1 at a dose of 0.25, 0.5, or 1 mg u-PA equivalent/kg yielded 35% 2 5%, 41% 2 7% or 58% ? 7% lysis at 90 minutes, respectively. With the control conjugate rscu-PA/ MA-1C8, lysis at 90 minutes ranged from 20% 2 4% to 34% ? 8% at doses from 0.5 to 2 mg u-PA equivalentkg.
Linear regression analysis of the individual doseresponse data, expressed as percent lysis over the background value versus dose administered, yielded values for the relative thrombolytic potencies (percent lysis per u-PA equivalent administered) towards platelet-rich human plasma clots as summarized in Table 3 and illustrated in Fig  8A. With rscu-PA/MA-PMI-1, a threefold higher thrombolytic potency was found than with rscu-PA (58% 14% v 19% 2 2.4% lysis per mg u -P u g , P < ,0005). The thrombolytic potency of rscu-PA/MA-LIBS-1 was 2.3-fold higher than that of rscu-PA (43% 2 11% v 19% ? 2.4% lysis per mg u -P u g , P = .004). In contrast, conjugation of rscu-PA with the control antibody MA-1C8 resulted in a 2.3-fold decrease of its thrombolytic potency (8.3% ? 4.1% v 19% k 2.4% lysis per mg u-PA/kg, P = .023).
Linear regression analysis of the individual doseresponse data, expressed as percent lysis over the background value versus steady state plasma u-PA-related antigen level, yielded values for the specific thrombolytic activity (percent lysis per microgram per milliliter steady state plasma u-PA antigen level) towards platelet-rich human plasma clots as summarized in Table 3 and illustrated in Fig 8B. As compared with rscu-PA, specific thrombolytic activities were reduced 2.6-fold with rscu-PA/ MA-PMI-1 (P = .028), sixfold with rscu-PA/MA-LIBS-1 (P = .003), and 30-fold with the control conjugate rscu-PA/ MA-1C8 (P < .0005). No significant fibrinogen breakdown occurred during lysis with rscu-PA, but a,-antiplasmin levels at the end of the experiment were somewhat decreased (66% ? 10% residual a,-antiplasmin at a dose of 4 m a g ) . However, lysis with the conjugates was associated with fibrinogen breakdown and extensive a,-antiplasmin consumption at doses in excess of 0.5 mgikg u-PA equivalent. Plasma clearance rates, determined from the infusion rate and the steady state u-PA-related antigen levels in plasma, were approximately 0.64 mL/min for rscu-PA/MA-PMI-1, 0.48 mL/min for rscu-PA/MA-LIBS-1, and 0.54 mL/min for rscu-PA/MA-lC8, as compared with 4.9 mL/ min for rscu-PA (Table 3) .
Results of the in vivo thrombolytic potency of rscu-PA, rscu-PA/MA-PMI-1, rscu-PA/MA-LIBS-1, and rscu-PA/ MA-IC8 towards platelet-poor human plasma clots are summarized in Table 4 . Spontaneous lysis at 90 minutes was 22% t 3% (mean ? SEM, n = 6). With rscu-PA, lysis at 90 minutes increased from 30% ? 4% at 0.25 mgikg to 87% ? 7% at 2 mgikg. rscu-PNMA-PMI-1 at a dose of 0.5, 1, or 2 mg u-PA/kg yielded 24% ? 7%, 54% c 7%, and 61% ? 5% lysis, respectively, and with rscu-PA/MA-LIBS-1 at a dose of 0.25, 0.5, 1, and 2 mg u-PA/kg lysis at 90 minutes was 23% f 9%, 52% ? 4%, 67% f 11%, and 86% f 1%, respectively. rscu-PA/MA-lC8 at doses from 0.25 to 2 mg u-PA equivalentkg yielded lysis at 90 minutes ranging from 25% f 3% to 75% ? 1%.
The individual dose-response data, expressed as percent lysis over background versus dose administered, were analyzed by linear regression analysis yielding values for thrombolytic potencies towards platelet-poor human plasma clots as summarized in Table 4 and illustrated in Fig 8C . No significant differences were observed between rscu-PA and the conjugates (21% to 37% lysis per mg u-PA/kg, P > ,075).
Linear regression analysis of the individual doseresponse data, expressed as percent lysis over background versus steady state plasma u-PA-related antigen level, yielded values for specific thrombolytic activities towards platelet-poor human plasma clots as summarized in Table 4   Table 3 The data represent mean t SEM of the number of experiments indicated between parentheses. 'The plasma clearance rate (Clp) was calculated as the ratio of the infusion rate (pgimin) and the steady state plasma concentration of antigen (FgimL) at the end of the infusion, assuming an average body weight of 100 g.
tThe regression line slope was calculated from the individual dose-response data after correction for background lysis (saline), by linear regression forced through the origin. The data represent mean f SEM of the regression line slope and, in parentheses, the correlation coefficient of the regression line. and illustrated in Fig 8D. The specific thrombolytic activities of rscu-PA/MA-PMI-1, rscu-PA/MA-LIBS-1, and rscu-PA/MA-lC8 were, respectively, 8-, 6-, and 10-fold lower than that of rscu-PA (P < .005). Lysis with the conjugates was associated with extensive fibrinogen breakdown and a,-antiplasmin depletion ( Table 4 ). Plasma clearance rates were approximately 0.6 mL/min for the conjugates as compared with 5.8 mL/min for rscu-PA ( Table 4) .
DISCUSSION
One approach to improve the clot-selectivity of plasminogen activators consists of targeting the agent to the clot by conjugation with fibrin-specific MoAbs.25,26 Alternatively, plasminogen activators could be targeted to a platelet-rich clot using antiplatelet antibodies. In the present study, chemical conjugates were made of rscu-PA with four different well-characterized murine monoclonal antiplatelet antibodies9~".l2: MA-TSPI-1, directed against human thrombospondin; MA-PMI-2, directed against the platelet surface glycoprotein IIIa; MA-PMI-1, directed against GPIIba; and MA-LIBS-1, directed against GPIIIa. These antibodies only recognize epitopes on activated platelets and not, or much less, on unactivated platelet^.^*"^'^ The purified conjugates rscu-PNMA-TSPI-1, rscu-PAIMA-PMI-2, rscu-PA/MA-PMI-1, and rscu-PA/MA-LIBS-1 contained 34% to 45% of the total protein present in the coupling mixtures, with an average stoichiometry between The data represent mean 2 SEM of the number of experiments indicated in parentheses. *The plasma clearance rate (Clp) was calculated as the ratio of the infusion rate (Kgimin) and the steady state plasma concentration of antigen (pg/mL) at the end of the infusion, assuming an average body weight of 100 g.
tThe regression line slope was calculated from the individual dose-response data after correction for background lysis (saline), by linear regression forced through the origin. The data represent mean f SEM of the regression line slope with the correlation coefficient given in parentheses.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 1.6 and 1.8 IgG molecules per rscu-PA molecule. The specific activities on fibrin plates or chromogenic substrate and the kinetics of plasminogen activation of the rscu-PA moiety of each conjugate were comparable with those of unconjugated rscu-PA. In addition, conjugation of rscu-PA with antiplatelet antibodies did not alter its plasminogen activating potential in the presence or the absence of platelets or fibrin. All four conjugates were able to compete with the corresponding radiolabeled unconjugated antibody for binding to their antigen, although with a twofold to fourfold lower efficiency than the unconjugated antibodies. It is possible that the antigen-binding capacity of some of the conjugated antibody molecules may have been affected by the SPDP treatment or the conjugation.
Binding of rscu-PNMA-PMI-1 or rscu-PA/MA-LIBS-1 to ADP-stimulated platelets in plasma was threefold to fourfold higher than binding to unstimulated platelets. Similarly, binding of these conjugates to platelet-rich human plasma clots in a plasma milieu was twofold to 2.7-fold higher than binding to platelet-poor plasma clots. In addition, binding of both rscu-PNMA-PMI-1 and rscu-PNMA-LIBS-1 to ADP-stimulated platelets as well as to plateletrich clots was significantly higher than that of the control conjugate rscu-PNMA-1C8. Results obtained with unconjugated MA-LIBS-1 in these binding assays were comparable with those obtained with the conjugate of this antibody with rscu-PA. However, with unconjugated MA-PMI-1, binding to both ADP-stimulated platelets and platelet-rich clots was lower than with its conjugate rscu-PNMA-PMI-1. The reason for this difference is not clear.
ADP-induced platelet aggregation was partially inhibited after a 30-minute preincubation of the platelets with rscu-PA, rscu-PA/MA-PMI-1, or rscu-PA/MA-PMI-2. However, as compared with rscu-PA, equi-effective inhibition (75% residual platelet aggregation) with rscu-PNMA-PMI-1 or with rscu-PNMA-PMI-2 was obtained at 50-or 10-fold lower u-PA concentrations, respectively. This enhanced inhibitory effect of rscu-PA/MA-PMI-1 or rscu-PA/ MA-PMI-2 cannot be explained merely by interaction of MA-PMI-1 or MA-PMI-2 with their epitopes on GPIIb/ IIIa, because the antibodies alone did not inhibit platelet aggregation. Targeting of rscu-PA to the platelet surface may, however, result in localized plasminogen activation and breakdown of receptor-bound fibrinogen. ADPinduced platelet aggregation was also inhibited after preincubation of the platelets with the antibody MA-LIBS-1. However, the inhibition by MA-LIBS-1 presumably was not related to specific antigen-antibody interaction, because Fab fragments of this antibody did not inhibit platelet aggregation (not shown). Conjugation of MA-LIBS-1 with rscu-PA did not increase the inhibitory action further.
In an in vitro system composed of '251-fibrin-labeled platelet-rich human plasma clots immersed in citrated human plasma, none of the rscu-PNantiplatelet antibody conjugates appeared to have a higher fibrinolytic potency than unconjugated rscu-PA. The poor fibrinolytic potency of the rscu-PNantiplatelet antibody conjugates towards platelet-rich clots in vitro appeared not to be due to an impairment of the enzymatic activity of conjugated rscu-PA, because the biochemical properties of the u-PA moieties of each of the conjugates were comparable with those of rscu-PA. Furthermore, all four antiplatelet antibody/ rscu-PA conjugates were able to lyse platelet-poor clots prepared from normal human plasma, with a fibrinolytic potency similar or even slightly higher than that of rscu-PA; 50% lysis in 2 hours was obtained at a concentration of 0.7 to 3 bg u-PNmL for the various conjugates, as compared with 1.25 &mL for rscu-PA. Recently, Bode et al obtained a 1.3-to 11-fold enhancement of the fibrinolytic potency of urokinase towards platelet-rich human plasma clots in vitro by conjugation of urokinase with the murine MoAb 7E3 directed against platelet membrane GPIIb/IIIa."
The in vivo thrombolytic potency of the different plasminogen activators towards platelet-rich human plasma clots was evaluated in a hamster pulmonary embolism model. Lysis of platelet-rich clots increased 2.3-to 3-fold by conjugation of rscu-PA with the anti-GPIIbIIIIa antibodies MA-PMI-1 or MA-LIBS-1. Moreover, thrombolysis with these rscu-PNantiplatelet antibody conjugates was fivefold to sevenfold higher than with the conjugate of rscu-PA with the control antibody MA-1C8. The thrombolytic potency of an anti-thrombospondin antibodylrscu-PA conjugate, rscu-PNMA-TSP5, with similar biochemical properties as rscu-PNMA-TSPI-1 described above (data not shown), was not significantly different from that of rscu-PA or of rscu-PA/ MA-1C8: 17% f 7% lysis per mg u-PA/kg v 19% 2 2.4% lysis per m a g for rscu-PA, P = .7, or v 8.3% * 4.1% lysis per mg u-PAkg for rscu-PNMA-1C8, P = .3.
Lysis of platelet-poor or platelet-rich clots in vivo with the different conjugates was associated, at higher concentrations, with fibrinogen breakdown and with extensive (yzantiplasmin consumption. Chemical conjugation of rscu-PA with antibodies thus seems to increase the potential for systemic activation of the fibrinolytic system, as was also previously observed for rscu-PNMA-1C8.6 This increased fibrinogenolytic effect of the conjugates was also indicated by the significant fibrinogen breakdown observed during in vitro clot lysis. The reason for the increased systemic activation with conjugated rscu-PA is not clear. With the antibodylrscu-PA conjugates, activation to two-chain moieties by plasmin occurred with initial activation rates that were comparable with the value found with rscu-PA. Thus, the difference in systemic activation between conjugated and unconjugated rscu-PA appears not to be related to differences in the rate of activation to two-chain moieties.
Conjugation of rscu-PA with MA-PMI-1 and MA-LIBS-1 as well as with MA-1C8 decreased its plasma clearance rate approximately 10-fold, yielding significantly higher steady state plasma u-PA antigen levels with the conjugates than with rscu-PA at comparable doses (Tables 3 and 4 ). The specific thrombolytic activities towards platelet-rich human plasma clots, determined as percent lysis per microgram per milliliter steady state plasma antigen level, were 2.6-and 6-fold lower for rscu-PNMA-PMI-1 and rscu-PNMA-LIBS-1, respectively, and 30-fold lower for rscu-PA/MA-1C8, as compared with rscu-PA. Specific thrombolytic activities towards platelet-poor human plasma clots were eightfold to 10-fold lower than for rscu-PA, both for For personal use only. on October 3, 2017. by guest www.bloodjournal.org From rscu-PA/MA-PMI-1 or rscu-PA/MA-LIBS-1 and for rscu-PNMA-lC8, resulting in similar thrombolytic potencies (potency at comparable dose). Thus, conjugation of rscu-PA per se reduces its in vivo thrombolytic potency, a finding that has been observed previously with similar chemical conjugates of rscu-PA with MoAbs.' With platelet-poor clots, the prolonged half-life of the conjugates apparently partially compensates for the loss of specific thrombolytic activity, resulting in similar thrombolytic potencies for conjugated and unconjugated rscu-PA. With platelet-rich clots, the additional targeting effect of the antiplatelet antibody moiety resulted in 2.3-to 3-fold enhanced thrombolytic potencies for rscu-PNMA-PMI-1 or rscu-PA/MA-LIBS-1 as compared with rscu-PA, and fivefold or sevenfold enhanced thrombolytic potencies as compared with the control conjugate rscu-PNMA-1C8.
With rscu-PA, lysis of platelet-rich clots in vivo occurred with a 1.8-fold lower efficiency than lysis of platelet-poor clots (19% 2 2.4% v 35% f 3.8% lysis per mgkg, P = .001).
Similarly, with rscu-PA/MA-lC8 lysis of platelet-rich clots in vivo was 3.8-fold less efficient than lysis of platelet-poor clots (8.3% f 4.1% v 32% 2 8.8% per mg u-PA/kg, P = .044). No significant difference was found between plateletrich and platelet-poor clots for lysis with rscu-PA/MA-LIBS-1 (43% f 11% v 37% f 6.8% lysis per mg u-PA/kg, P = ,636). In contrast, rscu-PA/MA-PMI-1 was 2.8-fold more efficient for lysing platelet-rich clots than plateletpoor clots (58% 2 14% v 21% f 6.2% lysis per mg u-PA/kg, P = .028).
In conclusion, chemical conjugates of rscu-PA with antiplatelet antibodies were functionally intact, both with respect to the in vitro enzymatic properties of rscu-PA and the antigen-binding capacity of the antibody. The thrombolytic potency of the conjugates towards platelet-rich human plasma clots in a hamster pulmonary embolism model was 2.3-to 3-fold increased as compared with unconjugated rscu-PA and was fivefold to sevenfold higher than the value obtained with a control conjugate. The relatively marginal improvement over rscu-PA appears to be due in part to a marked reduction of the specific thrombolytic activity of rscu-PA due to the conjugation procedure. Consequently, alternatively prepared conjugates, such as chimeric molecules obtained by recombinant DNA technology, might have maintained specific thrombolytic activities of rscu-PA and consequently have higher thrombolytic potencies.
